Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (10): 1004-1011.DOI: 10.3969/j.issn.1673-8640.2026.10.011
Previous Articles Next Articles
CHENG Guowei, LIU Qingyang, WANG Qiubo(
)
Received:2025-01-23
Revised:2025-10-11
Online:2026-10-30
Published:2026-10-20
CLC Number:
CHENG Guowei, LIU Qingyang, WANG Qiubo. Diagnostic value and biological function of integrin alpha 4 in peripheral blood mononuclear cells in rheumatoid arthritis[J]. Laboratory Medicine, 2026, 41(10): 1004-1011.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.10.011
| 基因名称 | 正向引物(5´~3´) | 反向引物(5´~3´) |
|---|---|---|
| ITGA4 | GAACCGATGGCTCCTAGTGG | GAAAGTGTGACCCCCAACCA |
| TNF-α | GTGCTTGTTCCTCAGCCTCT | ATGGGCTACAGGCTTGTCAC |
| IL-1β | CCAGCTACGAATCTCCGACC | TCGTGCACATAAGCCTCGTT |
| IL-6 | AGAGGCACTGGCAGAAAACA | GCTCTGGCTTGTTCCTCACT |
| GAPDH | GTCAAGGCTGAGAACGGGAA | AAATGAGCCCCAGCCTTCTC |
| 基因名称 | 正向引物(5´~3´) | 反向引物(5´~3´) |
|---|---|---|
| ITGA4 | GAACCGATGGCTCCTAGTGG | GAAAGTGTGACCCCCAACCA |
| TNF-α | GTGCTTGTTCCTCAGCCTCT | ATGGGCTACAGGCTTGTCAC |
| IL-1β | CCAGCTACGAATCTCCGACC | TCGTGCACATAAGCCTCGTT |
| IL-6 | AGAGGCACTGGCAGAAAACA | GCTCTGGCTTGTTCCTCACT |
| GAPDH | GTCAAGGCTGAGAACGGGAA | AAATGAGCCCCAGCCTTCTC |
| 项目 | 例数 | 年龄/岁 | 性别 | BMI/(kg·m-2) | RF/ (U·mL-1) | 抗CCP抗体/(U·mL-1) | ESR/(mm·h-1) | 病程/年 | DAS28评分/分 | 使用DMARD/[例(%)] | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 男/例 | 女/例 | ||||||||||
| RA组 | 85 | 58.04±1.33 | 33 | 52 | 23.09±0.43 | 28.54±6.33 | 8.42±2.42 | 20.61±5.87 | 4.20±1.03 | 3.17±0.95 | 76 |
| 正常对照组 | 100 | 55.53±2.61 | 32 | 68 | 22.33±0.53 | 7.8±1.03 | 1.62±0.76 | ||||
| 统计值 | 1.55 | 0.288 | 2.43 | 28.74 | 24.63 | ||||||
| P值 | 0.54 | 0.34 | 0.76 | <0.001 | <0.001 | ||||||
| 项目 | 例数 | 年龄/岁 | 性别 | BMI/(kg·m-2) | RF/ (U·mL-1) | 抗CCP抗体/(U·mL-1) | ESR/(mm·h-1) | 病程/年 | DAS28评分/分 | 使用DMARD/[例(%)] | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 男/例 | 女/例 | ||||||||||
| RA组 | 85 | 58.04±1.33 | 33 | 52 | 23.09±0.43 | 28.54±6.33 | 8.42±2.42 | 20.61±5.87 | 4.20±1.03 | 3.17±0.95 | 76 |
| 正常对照组 | 100 | 55.53±2.61 | 32 | 68 | 22.33±0.53 | 7.8±1.03 | 1.62±0.76 | ||||
| 统计值 | 1.55 | 0.288 | 2.43 | 28.74 | 24.63 | ||||||
| P值 | 0.54 | 0.34 | 0.76 | <0.001 | <0.001 | ||||||
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| ITGA4 mRNA | 0.672(0.596~0.748) | 1.017 | 61.2 | 70.0 | 0.312 |
| RF | 0.840(0.782~0.898) | 9.703 | 74.7 | 82.7 | 0.574 |
| 抗CCP抗体 | 0.720(0.649~0.791) | 4.946 | 52.9 | 94.0 | 0.469 |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| ITGA4 mRNA | 0.672(0.596~0.748) | 1.017 | 61.2 | 70.0 | 0.312 |
| RF | 0.840(0.782~0.898) | 9.703 | 74.7 | 82.7 | 0.574 |
| 抗CCP抗体 | 0.720(0.649~0.791) | 4.946 | 52.9 | 94.0 | 0.469 |
| 组别 | 细胞凋亡率/% | 细胞周期 | ||
|---|---|---|---|---|
| G0/G1期/% | S期 | G2/M期/% | ||
| 对照组 | 11.51±3.54 | 70.03±1.04 | 11.05±1.22 | 9.34±1.33 |
| 阳性对照组 | 13.04±2.68 | 76.23±0.99* | 10.56±1.55 | 3.23±0.65* |
| 低Carotegrast组 | 17.22±4.64 | 70.02±1.45 | 11.03±1.34 | 8.88±1.02 |
| 高Carotegrast组 | 17.81±3.01 | 79.23±1.12* | 12.06±0.88 | 5.44±0.86* |
| 组别 | 细胞凋亡率/% | 细胞周期 | ||
|---|---|---|---|---|
| G0/G1期/% | S期 | G2/M期/% | ||
| 对照组 | 11.51±3.54 | 70.03±1.04 | 11.05±1.22 | 9.34±1.33 |
| 阳性对照组 | 13.04±2.68 | 76.23±0.99* | 10.56±1.55 | 3.23±0.65* |
| 低Carotegrast组 | 17.22±4.64 | 70.02±1.45 | 11.03±1.34 | 8.88±1.02 |
| 高Carotegrast组 | 17.81±3.01 | 79.23±1.12* | 12.06±0.88 | 5.44±0.86* |
| [1] | Jang S, Kwon E J, Lee J J. Rheumatoid arthritis:pathogenic roles of diverse immune cells[J]. Int J Mol Sci, 2022, 23(2). |
| [2] | Chastney M R, Conway J R W, Ivaska J. Integrin adhesion complexes[J]. Curr Biol, 2021, 31(10):R536-R542. |
| [3] |
Aman J, Margadant C. Integrin-dependent cell-matrix adhesion in endothelial health and disease[J]. Circ Res, 2023, 132(3):355-378.
DOI PMID |
| [4] |
Rossi B, Dusi S, Angelini G, et al. Alpha4 beta7 integrin controls Th17 cell trafficking in the spinal cord leptomeninges during experimental autoimmune encephalomyelitis[J]. Front Immunol, 2023, 14:1071553.
DOI URL |
| [5] | Calma A D, Young S, Sandbach J, et al. Targeting alpha-4 integrin with natalizumab for intermediate uveitis associated with multiple sclerosis[J]. Mult Scler J Exp Transl Clin, 2024, 10(4):20552173241301034. |
| [6] |
Matsouka K, Watanabe M, Ohmori T, et al. AJM300(carotegrast methyl),an oral antagonist of alpha4-integrin,as induction therapy for patients with moderately active ulcerative colitis:a multicentre,randomised,double-blind,placebo-controlled,phase 3 study[J]. Lancet Gastroenterol Hepatol, 2022, 7(7):648-657.
DOI URL |
| [7] |
Alsadhan A, Chen J, Gaglione E M, et al. CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy[J]. Clin Cancer Res, 2023, 29(18):3612-3621.
DOI URL |
| [8] | 中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志, 2018, 57(4):42-51. |
| [9] |
Prevoo M L, Van'T Hof M A, Kuper H H, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis[J]. Arthritis Rheum, 1995, 38(1):44-48.
DOI URL |
| [10] | Van Riel P L, Renskers L. The disease activity score(DAS) and the disease activity score using 28 joint counts(DAS28) in the management of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2016, 34(5Suppl 101): S40-S44. |
| [11] |
Wu Z, Ma D, Yang H, et al. Fibroblast-like synoviocytes in rheumatoid arthritis:surface markers and phenotypes[J]. Int Immunopharmacol, 2021, 93:107392.
DOI URL |
| [12] |
Alivernini S, Firesteun G S, Mcinnes I B. The pathogenesis of rheumatoid arthritis[J]. Immunity, 2022, 55(12):2255-2270.
DOI PMID |
| [13] |
Venetsanopoulou A I, Alamanos Y, Voulgari P V, et al. Epidemiology of rheumatoid arthritis:genetic and environmental influences[J]. Expert Rev Clin Immunol, 2022, 18(9):923-931.
DOI URL |
| [14] |
Cush J J. Rheumatoid arthritis:early diagnosis and treatment[J]. Rheum Dis Clin North Am, 2022, 48(2):537-547.
DOI URL |
| [15] |
Sepriano A, Kerschbaumer A, Bergstra S A, et al. Safety of synthetic and biological DMARDs:a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis[J]. Ann Rheum Dis, 2023, 82(1):107-118.
DOI URL |
| [16] |
Polman C H, O'Connor P W, Havrdova E, et al. A randomized,placebo-controlled trial of natalizumab for relapsing multiple sclerosis[J]. N Engl J Med, 2006, 354(9):899-910.
DOI URL |
| [17] |
Feagan B G, Greenberg G R, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin[J]. N Engl J Med, 2005, 352(24):2499-2507.
DOI URL |
| [18] |
Khoy K, Mariotte D, Defer G, et al. Natalizumab in multiple sclerosis treatment:from biological effects to immune monitoring[J]. Front Immunol, 2020, 11:549842.
DOI URL |
| [19] |
Ohmori T. Real-world effectiveness and safety of carotegrast methyl in Japanese patients with moderately active ulcerative colitis[J]. Inflamm Intest Dis, 2024, 9(1):271-282.
DOI PMID |
| [20] |
Chu H W, Schaunaman N. Very late antigen-4:a novel receptor for club cell secretory protein 16 to control inflammation[J]. Am J Respir Crit Care Med, 2021, 203(11):1340-1341.
DOI URL |
| [21] | Savino W, Chaves B, Bonomo A C, et al. Integrin-directed antibody-based immunotherapy:focus on VLA-4[J]. Immunother Adv, 2021, 1(1):ltab002. |
| [22] |
Barbadillo C, Ag A, Salas C, et al. Anti-integrin immunotherapy in rheumatoid arthritis:protective effect of anti-alpha 4 antibody in adjuvant arthritis[J]. Springer Semin Immunopathol, 1995, 16(4):427-436.
PMID |
| [23] |
Birner U, Issekutz T B, Walter U, et al. The role of alpha(4) and LFA-1 integrins in selectin-independent monocyte and neutrophil migration to joints of rats with adjuvant arthritis[J]. Int Immunol, 2000, 12(2):141-150.
PMID |
| [24] |
Dhillon S. Carotegrast methyl:first approval[J]. Drugs, 2022, 82(9):1011-1016.
DOI |
| [25] | Takeuchi E, Tanaka T, Umemoto E, et al. VLA-4-dependent and -independent pathways in cell contact-induced proinflammatory cytokine production by synovial nurse-like cells from rheumatoid arthritis patients[J]. Arthritis Res, 2002, 4(6):R10. |
| [26] | Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis[J]. Int J Mol Sci, 2021, 22(20). |
| [27] |
Ran Y, Dong Y, LI Y, et al. Mesenchymal stem cell aggregation mediated by integrin alpha4/VCAM-1 after intrathecal transplantation in MCAO rats[J]. Stem Cell Res Ther, 2022, 13(1):507.
DOI PMID |
| [28] |
Dong M, Wang W, Wu W, et al. A novel surface marker CD49d promotes TNF expression in oyster agranulocytes by mediating the MAPK pathway[J]. Fish Shellfish Immunol, 2024, 151:109702.
DOI URL |
| [29] | Takeda T, Tsubak M, Genno S, et al. CD49d and CD49e induce cell adhesion-mediated drug resistance through the nuclear factor-kappaB pathway in Burkitt lymphoma[J]. J Physiol Pharmacol, 2020, 71(4). |
| [1] | WANG Li, TANG Ling, JIN Yaxiong, ZHANG Junlong, GAO Xuedan, NIU Qian. Roles of LDH,MO# and LMR in differential diagnosis of RA-ILD [J]. Laboratory Medicine, 2025, 40(6): 525-533. |
| [2] | LUO Jing, YUAN Jiayi, YAO Xiaoyan, FAN Lieying. Changes in cathepsin C expression in peripheral blood monocyte subsets of RA patients [J]. Laboratory Medicine, 2025, 40(10): 933-940. |
| [3] | ZHANG Feifei, WANG Jingwen, ZHANG Yuexin, ZHENG Dawei, MEN Xiang. Correlation between lncRNA MIR155HG and pulmonary function in patients with COPD and its auxiliary diagnosis value for AECODP [J]. Laboratory Medicine, 2024, 39(1): 31-36. |
| [4] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [5] | YANG Yanmin, PENG MengLe, LIAN Wenping. MDSC percentage and the expressions of RORα mRNA,IL-17E mRNA and FOXP3 mRNA in rectal cancer patients [J]. Laboratory Medicine, 2023, 38(1): 23-27. |
| [6] | HE Yaya, CHEN Shanshan, LI Yongsheng, LIU Juan. Expressions of sLAIR-1 and LAIR-1 mRNA in AS patients and their relationship with disease activity [J]. Laboratory Medicine, 2022, 37(10): 915-920. |
| [7] | ZHANG Wei, GUO Huijuan, WU Ximei, LING Xiuting, JIANG Xiaoxin, LIU Yunhong. Application value of serum sST2 level in monitoring rheumatoid arthritis and therapeutic effect [J]. Laboratory Medicine, 2021, 36(12): 1238-1242. |
| [8] | ZHOU Fujiang, WU Chengbin, GAO Shouxia, XU Chao, QIAN Wenying, HUANG Qiulan. Role of IDO/TTS ratio in the exclusion and disease assessment of RA [J]. Laboratory Medicine, 2020, 35(4): 304-309. |
| [9] | LIU Yixin, WEI Wei, WANG Yang, BAI Yingyu, WAN Chunyou, MA Jun, ZHENG Fang. TNF and CRT dual signaling for promoting NLRP3 inflammasome activation in synoviocytes for RA patients [J]. Laboratory Medicine, 2020, 35(4): 363-369. |
| [10] | WANG Xing, MA Yan, WANG Shengnan, ZHANG Heqian, LIU Rongzeng. Association of TIM-3 rs1036199 polymorphisms with the onset risk of rheumatoid arthritis:a Meta analysis [J]. Laboratory Medicine, 2019, 34(12): 1101-1106. |
| [11] | ZHANG Cui. Expression levels of microRNA-132 and high-mobility group box-1 protein in peripheral blood mononuclear cells of children with sepsis [J]. Laboratory Medicine, 2018, 33(9): 815-818. |
| [12] | DING Bingyu, LIN Ping, LI Qingtian. Th1/Th2 cytokines secreted by phytohaemagglutinin-stimulated peripheral blood mononuclear cells for the diagnosis of Alzheimer's disease [J]. Laboratory Medicine, 2018, 33(4): 290-294. |
| [13] | CHEN Yiqiong, ZHAO Di, REN Fang, DENG Xiaogang, XU Long, LI Zhi. Relationship between anti-carbamylated protein antibody and rheumatoid arthritis [J]. Laboratory Medicine, 2018, 33(1): 26-30. |
| [14] | LI Yunchun, ZHONG Li, WANG Yue, FANG Zhongjun, DING Liumei, SU Qizhu. Correlations of red blood cell distribution width and related inflammation factors with disease activity in patients with rheumatoid arthritis [J]. Laboratory Medicine, 2017, 32(4): 304-307. |
| [15] | XIE Zejin, WANG Houzhao, LIN Yi. CD62p,IL-6 and hs-CRP levels in rheumatoid arthritis [J]. Laboratory Medicine, 2017, 32(11): 966-969. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||